🇺🇸 FDA
Patent

US 12122843

High affinity monoclonal antibodies targeting glypican-1 and methods of use

granted A61KA61K2039/505A61K2039/852

Quick answer

US patent 12122843 (High affinity monoclonal antibodies targeting glypican-1 and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K2039/505, A61K2039/852, A61K47/6829, A61K47/6929